arrow
M

Miguel Canales

clínica universidad de navarra and instituto de investigación sanitaria de navarra
H指数:31
被引数:4,471

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Integrated Single-Cell and Spatial Multi-Omics of Clonal Precursors and Immune Niches in Germinal Center Lymphomas

整合克隆前体和免疫微环境的生发中心淋巴瘤的单细胞与空间多组学分析

Cancers
IF4.4
2026-04-030
OAAI
Analysis of peripheral neuropathy in the POLARIX study using clinician- and patient-reported outcomes

POLARIX研究中使用临床医生和患者报告结局对周围神经病变的分析

2025-03-170
OA
Prognostic risk and survival of asymptomatic IgM monoclonal gammopathy: Results from a Spanish Multicenter Registry
2024-11-120
OAAI
Anthracycline-induced cardiovascular toxicity: validation of the Heart Failure Association and International Cardio-Oncology Society risk score
2024-08-064
OA
Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)
2023-11-179
OAAI
Parsaclisib, a PI3Kd inhibitor, in relapsed and refractory follicular lymphoma (CITADEL-203): a phase 2 study

Parsaclisib,一种PI3Kd抑制剂,用于复发和难治性滤泡性淋巴瘤 (CITADEL-203): 一项2期研究

2023-09-013
OAAI
Hydrodynamics, Hydrochemistry, and Stable Isotope Geochemistry to Assess Temporal Behavior of Seawater Intrusion in the La Yarada Aquifer in the Vicinity of Atacama Desert, Tacna, Peru

水动力,水化学和稳定同位素地球化学,以评估秘鲁塔克纳阿塔卡马沙漠附近La Yarada含水层中海水入侵的时间行为

2021-11-0918
OA
Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study
2021-07-1611
OAAI
Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma
2021-02-026
OA
Cardiovascular risk factors during cancer treatment. Prevalence and prognostic relevance: insights from the CARDIOTOX registry
2020-11-0745
PREAI
Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study
2020-10-08180
OAAI
Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry
2020-02-04161
OA
A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy
2018-05-1057
OAAI